Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
September 2023 Vol 16, Payers' Guide to FDA Updates
Welcome to the 2023 PAYERS’ GUIDE TO FDA UPDATES: Latest Approvals, Upcoming Decisions
Read More
A Payer Perspective
Challenges Facing the US Healthcare System in 2023 and Beyond: A Payer Perspective
Gary M. Owens, MD
Read More
FDA Approvals
IMJUDO (Tremelimumab-actl) in Combination With IMFINZI (Durvalumab) Receives FDA Approval for HCC and NSCLC
Jerm Day-Storms, PhD, MWC
Read More
FDA Approvals
FDA Approval of SYFOVRE (Pegcetacoplan) and IZERVAY (Avacincaptad Pegol) Reshapes Management of GA
Jerm Day-Storms, PhD, MWC
Read More
FDA Approvals
FDA Pipeline, October-December 2023
Read More
FDA Approvals
FDA Approvals of Brand-Name Prescription Drugs, October 4, 2022, Through August 4, 2023
Read More
Results 1 - 6 of 6
